A nationwide study investigating whether simple blood tests could revolutionize dementia diagnosis within the NHS has reached a significant milestone by enrolling its 500th participant.
Alexander McCreadie, a 75-year-old Bath resident and Army veteran, became the landmark volunteer after attending ReMind UK, the independent charity running NHS memory clinic services in Bath and North East Somerset. Alexander was diagnosed with mild cognitive impairment (MCI) in 2024 after he and his wife noticed early signs of forgetfulness.
Born in Scotland and now living in Bath for 26 years, Alexander served in the Army for 25 years before working in health and safety in the mobile crane industry. He stays active enjoying bowling and spending time with his large family, including five children, 11 grandchildren, and three great-grandchildren.
READ MORE: Mary Berry’s Spiced Orange Cake: A Festive Delight Ready in 25 Minutes
READ MORE: Inspired Northampton Saints End Bath Rugby’s Unbeaten Home Run
Eager to contribute to research, Alexander said, “If sharing my experience helps others understand memory problems better and breaks down the stigma attached to dementia, that’s a positive step. Fear and misunderstanding often prevent people from seeking help or talking openly.” He hopes his participation will encourage further research crucial for improving diagnosis and developing effective treatments. “The more we learn, the better life will be for those living with dementia,” he added.
The Read-out (Real World Dementia Outcomes) study forms part of the Blood Biomarker Challenge, a multimillion-pound initiative led by Alzheimer’s Society and Alzheimer’s Research UK. It is supported by the National Institute for Health and Care Research, Gates Ventures, and funds raised by players of the People’s Postcode Lottery.
Dr Tom Welsh, research and medical director at ReMind UK, highlighted the importance of reaching the 500-participant milestone. “We are proud that Bath was the location for this milestone,” he said. “Our thanks go to Alex and all participants who are helping build evidence to improve dementia diagnosis for the entire NHS.”
Volunteers in the Read-out study provide blood samples and cognitive health information, allowing researchers to assess how accurately various blood tests detect Alzheimer’s disease, vascular dementia, frontotemporal dementia, and dementia with Lewy bodies. The study focuses on testing these biomarkers across different populations, including older adults and individuals with conditions like kidney disease.
Professor Vanessa Raymont, associate director at Dementias Platform UK and lead researcher, called the milestone a remarkable achievement within just one year of the study launching. “We’re at an exciting juncture in dementia research, with emerging drugs that can slow early Alzheimer’s. Yet these treatments require early and accurate diagnosis to reach those who can benefit,” she explained. “Blood biomarkers could revolutionize diagnosis and ensure timely treatment options.”
ReMind UK is one of 33 Dementias Platform UK (DPUK) sites incorporating NHS memory clinics and community research services. While 22 centres are active, another 12 are expected to join in 2026, aiming to recruit over 3,100 participants from diverse backgrounds.
This study also supports NHS England’s efforts to raise the UK dementia diagnosis rate, currently at 65.6%, closer to its target of 66.7%. The Read-out study runs alongside the Adapt trial, launched in September 2025, which is testing a specific blood biomarker for improved diagnostic accuracy.
Laura Chow, head of charities at People’s Postcode Lottery, welcomed the milestone. “Early diagnosis is vital in the fight against dementia. We’re proud to support research with the potential to transform detection and care,” she said.
Anyone concerned about dementia symptoms is encouraged to contact their GP or visit the relevant services to seek advice.